{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:05:51Z","timestamp":1784808351460,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ceramide is a central molecule of sphingolipid metabolism and is involved in the development of non\u2010alcoholic fatty liver disease (NAFLD) and non\u2010alcoholic steatohepatitis (NASH). It has already been reported that the inhibition of serine palmitoyltransferase (SPT), the rate\u2010limiting enzyme in the sphingolipid biosynthetic pathway, has an inhibitory effect on hepatic lipidosis, but its effect on severe hepatic fibrosis is not clear. In this study, we examined whether a SPT inhibitor could suppress the activation of hepatic stellate cells (HSC) and ameliorate the progression of NASH. Effects on sphingolipid metabolism and HSC activation marker genes by NA808, a SPT inhibitor, were evaluated in an immortalized HSC cell line (E14C12). NA808 decreased sphingolipid synthesis and the expression of \u03b1\u2010smooth muscle actin (\u03b1\u2010SMA) and collagen 1A1 mRNA in HSC. We identified a novel oral SPT inhibitor, CH5169356, which is a prodrug of NA808. CH5169356 was administered in the Ath+HF model, a NASH mouse model with liver fibrosis induced by atherogenic and high\u2010fat content diets. CH5169356 showed a significant decrease in the expression of \u03b1\u2010SMA and collagen 1A1 mRNA in the liver and an inhibition of liver fibrosis progression. CH5169356 was also evaluated in a Stelic animal model (STAM), a NASH mouse model induced through a different mechanism than that of the Ath+HF model, and showed a significant anti\u2010fibrotic effect. In conclusion, CH5169356 could inhibit the progression of hepatic fibrosis in the pathogenesis of NASH by suppressing HSC activation, suggesting that CH5169356 would be a potential oral NASH therapeutic agent.<\/jats:p>","DOI":"10.1002\/prp2.1094","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:16:13Z","timestamp":1684480573000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non\u2010alcoholic steatohepatitis (NASH)"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3243-2056","authenticated-orcid":false,"given":"Natsuko","family":"Hada","sequence":"first","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Yokohama city Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Katsume","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Yokohama city Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawasaki","family":"Kenichi","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Yokohama city Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Translational Research Division Chugai Pharmaceutical Co., Ltd.  Yokohama city Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Horiba","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd.  Yokohama city Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sudoh","sequence":"additional","affiliation":[{"name":"Department of Translational Research, Joint Research Center for Human Retrovirus Infection Kagoshima University  Kagoshima city Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.033"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040792"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2329"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.014"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2006.07.001"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21874"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53346-4"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-013-0016-1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep12466"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.38"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22572"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.091257"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio742"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.012"},{"key":"e_1_2_10_16_1","unstructured":"KatoT KimuraN MizutaniA et al.Process for producing compound with anti\u2010HCV potency and intermediate for use therein. Publication No.WO2006088071.2006."},{"key":"e_1_2_10_17_1","unstructured":"KohchiY NakamaK KomiyamaS WatanabeF.Orally administrable viridiofungin derivative having anti\u2010HCV activity. Publication No. WO\/2014\/027696.2014"},{"key":"e_1_2_10_18_1","first-page":"731","article-title":"Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat\u2010storing) cells","volume":"72","author":"Murakami K","year":"1995","journal-title":"Lab Invest"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410078200"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12184"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"issue":"1","key":"e_1_2_10_22_1","first-page":"S21","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: G protein\u2013coupled receptors","volume":"176","author":"Alexander SPH","year":"2019","journal-title":"Br J Pharmacol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.107"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26606"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807800200"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126910"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00934.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.04.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.12.008"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.09.015"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-1-12"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.78525"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00579"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800496-JLR200"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.028"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1318"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P056002"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0071"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.002"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00815.x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-018-0855-9"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1118-0"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115157"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.477786"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M063511"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00665"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12331"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12008"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1242\/bio.041251"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01356-2"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.1094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:51:05Z","timestamp":1784807465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/prp2.1094"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1094","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"2023-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01094"}}